Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE)

Drug Development Research

Volumn 75, Issue 3, 2014, Pages 172-188

  Wang, Denong ^a   Bhat, Roopa ^b   Sobel, Raymond A ^b   Huang, Wei ^c   Wang, Lai Xi ^c   Olsson, Tomas ^d   Steinman, Lawrence ^b  

^a SRI INTERNATIONAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

autoantibodies; biomarkers; cerebrospinal fluid; cryptic glycans; encephalomyelitis; glycomics; multiple sclerosis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EPITOPE; GLYCAN; MANNOSE OLIGOSACCHARIDE; SUGAR; ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MANNOSIDASE; MANNOSYL-OLIGOSACCHARIDE 1,2-ALPHA-MANNOSIDASE; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; BLOOD SAMPLING; CELL TYPE; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN MICROARRAY; ADULT; ANIMAL; BRAIN; IMMUNOLOGY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; SPINAL CORD; YOUNG ADULT;

ADULT; ANIMALS; ANTIGENS; AUTOANTIBODIES; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MANNOSIDASES; MICE; MICROARRAY ANALYSIS; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYSACCHARIDES; SPINAL CORD; YOUNG ADULT;

EID: 84900467152     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21169     Document Type: Article

References (52)

1. Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR,. 2008. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 82: 6359-6368.
2. Beyer NH, Lueking A, Kowald A, Frederiksen JL, Heegaard NH,. 2012. Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 242: 26-32.
3. Breloy I, Pacharra S, Aust C, Hanisch FG,. 2012a. A sensitive gel-based global O-glycomics approach reveals high levels of mannosyl glycans in the high mass region of the mouse brain proteome. Biol Chem 393: 709-717.
4. Breloy I, Pacharra S, Ottis P, Bonar D, Grahn A, Hanisch FG,. 2012b. O-linked N,Nâ€-diacetyllactosamine (LacdiNAc)-modified glycans in extracellular matrix glycoproteins are specifically phosphorylated at subterminal N-acetylglucosamine. J Biol Chem 287: 18275-18286.
5. Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, Seraj H, Hill HR, Fire E, Spector L, Yarden J, et al. 2009. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 217: 95-101.
6. Brooks SA, Dwek MV, Schumacher U,. 2002. Functional & Molecular Glycobiology. Oxford, BIOS Scientific Publishers Ltd.
7. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071.
8. Chai W, Yuen CT, Feizi T, Lawson AM,. 1999a. Core-branching pattern and sequence analysis of mannitol-terminating oligosaccharides by neoglycolipid technology. Anal Biochem 270: 314-322.
9. Chai W, Yuen CT, Kogelberg H, Carruthers RA, Margolis RU, Feizi T, Lawson AM,. 1999b. High prevalence of 2-mono- and 2,6-di-substituted manol-terminating sequences among O-glycans released from brain glycopeptides by reductive alkaline hydrolysis. Eur J Biochem 263: 879-888.
10. Genain CP, Cannella B, Hauser SL, Raine CS,. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5: 170-175.
11. Hakomori S,. 1985. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45: 2405-2414.
12. Han MH, Lundgren DH, Jaiswal S, Chao M, Graham KL, Garris CS, Axtell RC, Ho PP, Lock CB, Woodard JI, et al. 2012. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J Exp Med 209: 1325-1334.
13. Ho PP, Kanter JL, Johnson AM, Srinagesh HK, Chang EJ, Purdy TM, van Haren K, Wikoff WR, Kind T, Khademi M, et al. 2012. Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci Transl Med 4: 137ra73.
14. Hueber W, Utz PJ, Steinman L, Robinson WH,. 2002. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 4: 290-295.
15. Kabat EA, Berg D,. 1953. Dextran; an antigen in man. J Immunol 70: 514-532.
16. Kabat EA, Glusman M, Knaub V,. 1948. Immunochemical estimation of albumin and gamma globulin in normal and pathological cerebrospinal fluid. Trans Am Neurol Assoc 73 (73 Annual Meet.): 93.
17. Kabat EA, Wolf A, Bezer AE, Murray JP,. 1951. Studies on acute disseminated encephalomyelitis produced experimentally in rhesus monkeys. J Exp Med 93: 615-633.
18. Kabat EA, Liao J, Bretting H, Franklin EC, Geltner D, Frangione B, Koshland ME, Shyong J, Osserman EF,. 1980. Human monoclonal macroglobulins with specificity for Klebsiella K polysaccharides that contain 3,4-pyruvylated-D- galactose and 4,6-pyruvylated-D-galactose. J Exp Med 152: 979-995.
19. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH,. 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 12: 138-143.
20. Lehmann PV, Forsthuber T, Miller A, Sercarz EE,. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358: 155-157.
21. Lolli F, Mulinacci B, Carotenuto A, Bonetti B, Sabatino G, Mazzanti B, D'Ursi AM, Novellino E, Pazzagli M, Lovato L, et al. 2005. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci USA 102: 10273-10278.
22. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD,. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182: 75-85.
23. Michele DE, Campbell KP,. 2003. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem 278: 15457-15460.
24. Newsom-Davis TE, Wang D, Steinman L, Chen PF, Wang LX, Simon AK, Screaton GR,. 2009. Enhanced immune recognition of cryptic glycan markers in human tumors. Cancer Res 69: 2018-2025.
25. Ogawa G, Kaida K, Kuwahara M, Kimura F, Kamakura K, Kusunoki S,. 2013. An antibody to the GM1/GalNAc-GD1a complex correlates with development of pure motor Guillain-Barre syndrome with reversible conduction failure. J Neuroimmunol 254: 141-145.
26. Pacharra S, Hanisch FG, Breloy I,. 2012. Neurofascin 186 is O-mannosylated within and outside of the mucin domain. J Proteome Res 11: 3955-3964.
27. Raine CS, Cannella B, Hauser SL, Genain CP,. 1999. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 46: 144-160.
28. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, et al. 2002. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 8: 295-301.
29. Robinson WH, Fontoura P, Lee BJ, de Vegvar HE, Tom J, Pedotti R, DiGennaro CD, Mitchell DJ, Fong D, Ho PP, et al. 2003. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 21: 1033-1039.
30. Schachter H,. 1991. The "yellow brick road" to branched complex N-glycans. Glycobiology 1: 453-461.
31. Schwarz M, Spector L, Gargir A, Shtevi A, Gortler M, Altstock RT, Dukler AA, Dotan N,. 2003. A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody. Glycobiology 13: 749-754.
32. Schwarz M, Spector L, Gortler M, Weisshaus O, Glass-Marmor L, Karni A, Dotan N, Miller A,. 2006. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 244: 59-68.
33. Shahrizaila N, Yuki N,. 2011. Antiganglioside antibodies in Guillain-Barre syndrome and its related conditions. Expert Rev Neurother 11: 1305-1313.
34. Steinman L,. 1996. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85: 299-302.
35. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H,. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
36. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
37. Wang D,. 2003. Carbohydrate microarrays. Proteomics 3: 2167-2175.
38. Wang D,. 2004. Carbohydrate antigens. In:, Meyers RA, editor. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Wiley-VCH, Weinheim, Germany, p 277-301. II.
39. Wang D,. 2012a. Carbohydrate antigen microarrays. Methods Mol Biol 808: 241-249.
40. Wang D,. 2012b. N-glycan cryptic antigens as active immunological targets in prostate cancer patients. J Proteomics Bioinform 5: 90-95.
41. Wang D, Kabat EA,. 1996. Carbohydrate antigens (polysaccharides). In:, Regenmortal MHVV, editor. Structure of Antigens. Boca Raton. New York. London. Tokyo, CRC Press, p 247-276.
42. Wang D, Lu J,. 2004. Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV. Physiol Genomics 18: 245-248.
43. Wang D, Liu S, Trummer BJ, Deng C, Wang A,. 2002. Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. Nat Biotechnol 20: 275-281.
44. Wang D, Herzenberg LA, Steinman L, 2005. A lipid-based microarray and methods of use thereof. PCT International application No. PCT/US2006/011544, filed March 22, 2006, claiming benefit of U.S. Provisional Application no. 60/664 251, filed March 20, 2005.
45. Wang D, Dafik L, Nolley R, Huang W, Wolfinger RD, Wang LX, Peehl DM,. 2013. Anti-oligomannose antibodies as potential serum biomarkers of aggressive prostate cancer. Drug Dev Res 74: 65-80. Biomarkers in Drug Development and Companion Diagnostics.
46. Willison HJ,. 2002. Anti-glycolipid antibodies in the diagnosis of autoimmune neuropathies. Rev Neurol (Paris) 158 (12 Pt 2): S16-S20.
47. Willison HJ, Yuki N,. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125 (Pt 12): 2591-2625.
48. Yu M, Johnson JM, Tuohy VK,. 1996a. Generation of autonomously pathogenic neo-autoreactive Th1 cells during the development of the determinant spreading cascade in murine autoimmune encephalomyelitis. J Neurosci Res 45: 463-470.
49. Yu M, Johnson JM, Tuohy VK,. 1996b. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183: 1777-1788.
50. Yuen CT, Chai W, Loveless RW, Lawson AM, Margolis RU, Feizi T,. 1997. Brain contains HNK-1 immunoreactive O-glycans of the sulfoglucuronyl lactosamine series that terminate in 2-linked or 2,6-linked hexose (mannose). J Biol Chem 272: 8924-8931.
51. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, et al. 2004. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 101: 11404-11409.
52. Zink RC, Wolfinger RD, Mann G,. 2013. Summarizing the incidence of adverse events using volcano plots and time intervals. Clin Trials 10: 398-406.